RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update
RVL Pharmaceuticals plc (Nasdaq: RVLP) is set to release its first quarter 2022 financial results and provide a commercial update on May 12, 2022, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RVL Pharmaceuticals plc (Nasdaq: RVLP) is set to release its first quarter 2022 financial results and provide a commercial update on May 12, 2022, before U.S. markets open. The conference call will feature CEO Brian Markison and other executives discussing key financial metrics and business strategies. RVL focuses on underserved patient populations in ocular and medical aesthetics, currently commercializing UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution) 0.1%. Investors can access the live webcast and replay on the company’s website.
Positive
- Scheduled commercial update may indicate strong performance metrics.
- Focus on underserved markets could drive growth opportunities.
Negative
- None.
Details
News Market Reaction – RVLP
The recorded move for RVLP in the trading session of this news was +2.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET
BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a commercial update on Thursday, May 12, 2022, before U.S. financial markets open.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows:
| Date | Thursday, May 12, 2022 | |
| Time | 8:30 a.m. ET | |
| Toll free (U.S.) | 866-342-8591 | |
| International | 203-518-9713 | |
| Conference ID | RVLPQ122 | |
| Webcast (live and replay) | www.rvlpharma.com under the “Investors & News” section |
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution),
Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.